EVLO (Evelo Biosciences) YoY EBITDA Growth: 76.47% (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Evelo Biosciences YoY EBITDA Growth?

Evelo Biosciences EVLO -99.00% YoY EBITDA Growth is 76.47% as of Sep. 2023.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Evelo Biosciences's YoY EBITDA Growth for the quarter that ended in Sep. 2023 was 76.47%.

Evelo Biosciences's EBITDA per Share for the three months ended in Sep. 2023 was $-1.27.

Evelo Biosciences YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Evelo Biosciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences YoY EBITDA Growth Chart

Evelo Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY EBITDA Growth
Get a 7-Day Free Trial 63.84 -2.85 14.50 2.96 44.03

Evelo Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.85 62.84 59.47 55.13 76.47

Evelo Biosciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Evelo Biosciences's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EBITDA Growth (A: Dec. 2022 )
=(EBITDA per Share (A: Dec. 2022 )-EBITDA per Share (A: Dec. 2021 ))/ | EBITDA per Share (A: Dec. 2021 ) |
=(-24.522--43.81)/ | -43.81 |
=44.03 %

Evelo Biosciences's YoY EBITDA Growth for the quarter that ended in Sep. 2023 is calculated as:

YoY EBITDA Growth (Q: Sep. 2023 )
=(EBITDA per Share (Q: Sep. 2023 )-EBITDA per Share (Q: Sep. 2022 )) / | EBITDA per Share (Q: Sep. 2022 )) |
=(-1.271--5.401)/ | -5.401 |
=76.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 76.47% mean?
Evelo Biosciences (EVLO) has a YoY EBITDA Growth of 76.47% as of Sep. 2023. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Evelo Biosciences and its competitors.
Is Evelo Biosciences' YoY EBITDA Growth too high?
Evelo Biosciences' current YoY EBITDA Growth is 76.47%.
How does Evelo Biosciences' YoY EBITDA Growth compare to IMNN and EDSA?
Evelo Biosciences' YoY EBITDA Growth of 76.47% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Evelo Biosciences and its competitors. Evelo Biosciences's current YoY EBITDA Growth is 76.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evelo Biosciences stock overvalued right now?
Evelo Biosciences (EVLO) has a current YoY EBITDA Growth of 76.47%. The current YoY EBITDA Growth is 76.47%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Evelo Biosciences (EVLO), the current YoY EBITDA Growth is 76.47% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evelo Biosciences Business Description

Address 620 Memorial Drive, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.